Adaptimmune Therapeutics Q2 2024 GAAP EPS $0.04 May Not Be Comparable To $(0.08) Estimate, Sales $128.231 May Not Be Comparable To $38.483M Estimate
Portfolio Pulse from Benzinga Newsdesk
Adaptimmune Therapeutics reported Q2 2024 GAAP EPS of $0.04, which may not be comparable to the $(0.08) estimate. The company also reported sales of $128.231 million, which may not be comparable to the $38.483 million estimate.
August 12, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adaptimmune Therapeutics reported Q2 2024 GAAP EPS of $0.04, which may not be comparable to the $(0.08) estimate. The company also reported sales of $128.231 million, which may not be comparable to the $38.483 million estimate.
The reported EPS and sales figures are significantly different from the estimates, which could lead to positive market reactions due to the higher-than-expected sales and positive EPS.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100